50 results
8-K
EX-10.1
7kjfbe3y lcy1tf
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
424B5
63rck7i59
24 Mar 22
Prospectus supplement for primary offering
4:15pm
8-K
EX-99.1
kqt2a
26 Jan 22
Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022
8:15am
424B5
s7mv73mnrj s703iy
20 Aug 21
Prospectus supplement for primary offering
4:46pm
8-K
EX-1.1
zbcm8uz 5o
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
xqrreby
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am